We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
Read MoreHide Full Article
On Jun 22, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
This renowned home health and hospice services provider has outperformed its industry over the past six months. The stock has gained 22.7% against 4.1% decline of the industry in the said time frame.
The company noted that the COVID-19-led economic mayhem has had a mixed impact on the company’s business. Before the second week of March, Amedisys witnessed a decline in referral volumes and an increase in MIS visits. Beginning the second week of March, the company started to see a drop in MIS visits while witnessing steady recovery in referral volumes in all lines of businesses.
In hospice, while referrals hit a low, admission volumes have significantly improved. The company has already started to see signs of progress in episodes since March. Although the impact of COVID-19 ultimately led to increased lupus and lost building periods in this population (the full impact is expected in the second quarter), the company is confident that it can achieve its target improvements to mitigate the impact of behavioral assumptions once COVID-19 subsides.
Meanwhile, we note that, Amedisys is currently exploring opportunities in Home Health and Hospice segments. Amedisys has been benefiting from the recent acquisitions of hospice care providers — Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice (CCH).
However, elevated operating expenses and a declining gross margin continue to raise concerns. Further, an intensely competitive landscape and reimbursement woes weigh on the home health and hospice industry.
Key Picks
A few top-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Hologic, Inc. (HOLX - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 7%. The company presently has a Zacks Rank #2.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
On Jun 22, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
This renowned home health and hospice services provider has outperformed its industry over the past six months. The stock has gained 22.7% against 4.1% decline of the industry in the said time frame.
The company noted that the COVID-19-led economic mayhem has had a mixed impact on the company’s business. Before the second week of March, Amedisys witnessed a decline in referral volumes and an increase in MIS visits. Beginning the second week of March, the company started to see a drop in MIS visits while witnessing steady recovery in referral volumes in all lines of businesses.
In hospice, while referrals hit a low, admission volumes have significantly improved. The company has already started to see signs of progress in episodes since March. Although the impact of COVID-19 ultimately led to increased lupus and lost building periods in this population (the full impact is expected in the second quarter), the company is confident that it can achieve its target improvements to mitigate the impact of behavioral assumptions once COVID-19 subsides.
Amedisys, Inc. Price
Amedisys, Inc. price | Amedisys, Inc. Quote
Meanwhile, we note that, Amedisys is currently exploring opportunities in Home Health and Hospice segments. Amedisys has been benefiting from the recent acquisitions of hospice care providers — Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice (CCH).
However, elevated operating expenses and a declining gross margin continue to raise concerns. Further, an intensely competitive landscape and reimbursement woes weigh on the home health and hospice industry.
Key Picks
A few top-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Hologic, Inc. (HOLX - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic’s long-term earnings growth rate is estimated at 7%. The company presently has a Zacks Rank #2.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>